Hypertension

This page includes news and new technology on hypertension. The condition is caused by abnormally high blood pressure that causes excess force and pressure of the blood against the artery walls. Long-term, this can cause damage the vessels and contributes to heart disease. Therapies include antihypertensive medications such as diurestics and renal denervation therapy.

CinCor Pharma to be Acquired by AstraZeneca
January 9, 2023 — CinCor Pharma, Inc. announced that it has entered into a definitive agreement with AstraZeneca under which AstraZeneca has agreed to acquire CinCor. Marc de Garidel, Chief Executive ...
ReCor Medical Announces Results of RADIANCE II Pivotal Trial at TCT 2022 Annual Meeting
September 26, 2022 — ReCor Medical, Inc., a wholly owned subsidiary of Otsuka Medical Devices Co., Ltd., announced the detailed results from the RADIANCE II US FDA IDE pivotal trial evaluating the ...
ACC22: Transforming Cardiovascular Care
In April, the cardiology community converged face-to-face in Orlando for The American College of Cardiology’s (ACC22) Annual Scientific Session after a two-year hiatus that forced the conference to go ...
Pfizer Issues Voluntary Nationwide Recall of ACCUPRIL (Quinapril HCl)
April 25, 2022 — Pfizer is voluntarily recalling five (5) lots of Accupril (Quinapril HCl) tablets distributed by Pfizer to the patient (consumer/user) level due to the presence of a nitrosamine ...

Smidt Heart Institute investigators say condition, apparent resistant hypertension, is common, and a particular medication may get patients’ disease under control

News | Hypertension

Novel Study Deepens Knowledge of Treatment-Resistant Hypertension

September 22, 2023 — For many patients with hypertension--an elevated blood pressure that can lead to stroke or heart ...

September 22, 2023

IDE supported by data from the MODERATO II randomized pilot study that showed AVIM therapy drove significant and sustained reductions in blood pressure in hypertensive pacemaker patients

News | Hypertension

Orchestra BioMed Granted FDA Approval of IDE to Initiate BACKBEAT Pivotal Study of BackBeat CNT for the Treatment of Hypertension in Pacemaker Patients

September 20, 2023 — Orchestra BioMed Holdings, Inc., a biomedical company accelerating high-impact technologies to ...

September 20, 2023

All pregnant people should have their blood pressure measured at each prenatal visit

News | Hypertension

Task Force Issues Final Recommendation Statement on Screening for Hypertensive Disorders of Pregnancy

September 20, 2023 — The U.S. Preventive Services Task Force (Task Force) published a final recommendation statement on ...

September 20, 2023

The analysis of the health records found that, on average, participants’ systolic blood pressure increased by up to 1.7 mm Hg in the winter months compared to the summer months

News | Hypertension

Study from AHA Hypertension Scientific Sessions Reports on Cold Weather’s Impact on Treating High Blood Pressure

September 13, 2023 — Blood pressure among patients diagnosed with hypertension appeared to slightly increase, and rates ...

September 13, 2023

Mineralys Therapeutics, Inc. has presented final results from the Target-HTN Phase 2 trial of lorundrostat, a highly selective aldosterone synthase inhibitor, in individuals with uncontrolled hypertension (uHTN) and resistant hypertension (rHTN).

News | Cardiovascular Clinical Studies

Mineralys Therapeutics Presents Target-HTN Phase 2 Trial Results at 2023 AHA Hypertension Scientific Sessions

September 12, 2023 — Mineralys Therapeutics, Inc. has presented final results from the Target-HTN Phase 2 trial of ...

September 12, 2023

Recipient of the Harry Goldblatt Award for New Investigators from the American Heart Association’s 2023 Hypertension Council

News | Hypertension

Faulkner to be Honored by American Heart Association

September 7, 2023 —Jessica Faulkner, PhD, a physiologist whose research is focused on sex differences in cardiovascular ...

September 07, 2023

A new study in the AHA journal Hypertension finds SARS-CoV-2 infection is significantly associated with the development of high blood pressure in adults with preexisting heart conditions or those who were older, black or male.

News | Hypertension

Study Reveals COVID-19 May Trigger New-onset Hypertension

August 22, 2023 — An analysis of electronic medical records for more than 45,000 people found that COVID-19 infection ...

August 22, 2023

The Society for Cardiovascular Angiography & Interventions (SCAI) has released a position statement on Renal Denervation (RDN), emphasizing patient selection, optimal techniques, competence, training, and institutional recommendations

News | Renal Denervation

New SCAI Position Statement Highlights the Role of Renal Denervation in Hypertension Treatment

August 21, 2023 — The Society for Cardiovascular Angiography & Interventions (SCAI) has released a position statement on ...

August 21, 2023

New U.S. patent provides intellectual property (IP) protection until December 2040, and may qualify for term extension beyond 2040

News | Hypertension

Tenax Therapeutics Issued U.S. Patent for Oral Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

July 26, 2023 — Tenax Therapeutics, Inc, a specialty pharmaceutical company focused on identifying, developing and ...

July 26, 2023

Research shows that patients have better outcomes when they are treated at an accredited center, such as the Hypertension Center in the Smidt Heart Institute, by physicians specialized in the disease. Photo by Getty.

News | Hypertension

Smidt Heart Institute’s Hypertension Center Earns Accreditation

July 25, 2023 — The Hypertension Center in the Smidt Heart Institute at Cedars-Sinai has earned accreditation from the A ...

July 25, 2023

The results of a long-term analysis show necessary adjustments in international guidelines as well as in diagnosis and treatment

News | Hypertension

Chronic Thromboembolic Pulmonary Vascular Disease and Left Heart Disease are not Mutually Exclusive

April 28, 2023 — A long-term analysis designed by Christian Gerges and Irene Lang at the Department of Medicine II of ...

April 28, 2023

Findings from a clinical trial on treating hypertension, published in the Journal of the American Medical Association (JAMA), highlight the potential of personalized medicine in cardiovascular care, and in the future, could improve treatment adherence, patient outcomes, and the cost-effectiveness of blood pressure-lowering medication.

News | Hypertension

Study on Blood Pressure Treatment Sheds Light on Value of Personalized Medicine in Cardiovascular Care

April 12, 2023 — Results from the Precision Hypertension Care Study (PHYSIC) showed that personalized blood pressure ...

April 12, 2023

The need for appropriate diagnosis, treatment and reduction of lifestyle risk factors for high blood pressure in youth were outlined in a new scientific statement from the American Heart Association, published March 30 in the Association’s Hypertension journal.

News | Hypertension

Children with High Blood Pressure in Spotlight with AHA Journal Scientific Statement

April 4, 2023 — The need for appropriate diagnosis, treatment and reduction of lifestyle risk factors for high blood ...

April 04, 2023

Royal Philips has announced the debut of a comprehensive approach to telehealth with Philips Virtual Care Management. The solution’s condition-specific protocols now include heart disease and hypertension, as well as other chronic conditions. Photo credit: Getty Images

News | Remote Monitoring

Philips Debuts Remote Patient Management Solution

March 28, 2023 — Royal Philips has announced its debut of Philips Virtual Care Management, a comprehensive approach to ...

March 28, 2023

Use of an antihypertensive to lower blood pressure in obese patients was found effective, according to Target-HTN Trial results presented during the 2023 American College of Cardiology Scientific Session.

News | ACC

Data from Target-HTN Trial Released at ACC23 Supports Use of Antihypertensive to Reduce Blood Pressure in Obese Patients

March 9, 2023 — Positive results from a Mineralys Therapeutics study, the Target-HTN Phase 2 trial, demonstrated ...

March 09, 2023